ALLO
Allogene·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ALLO fundamentals
Allogene (ALLO) released its earnings on Nov 6, 2025: revenue was 0 (YoY 0.00%), missed estimates; EPS was -0.19 (YoY +40.63%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.19
+40.63%
Report date
Nov 6, 2025
ALLO Earnings Call Summary for Q3,2025
- 30% MRD Conversion Target: ALPHA3 trial aims for 30% MRD clearance in first-line lymphoma, benchmarked against 7% PFS improvement in autologous CAR-T (POLARIX).
- 2026 Milestones: Interim data readouts for cema-cel (H1 2026) and ALLO-329 autoimmune program (H1 2026).
- Financial Stability: $277M cash runway to mid-2027, with disciplined $150M annual cash burn.
- Platform Differentiation: Allogeneic manufacturing reduces costs by 70% vs. autologous, enabling off-the-shelf therapies at scale.
- Autoimmune Innovation: ALLO-329 targets CD19 and CD70, with built-in lymphodepletion to simplify administration in community settings.
EPS
Revenue
Revenue & Expenses
Key Indicators
Allogene (ALLO) key financial stats and ratios, covering profitability, financial health, and leverage.
Allogene (ALLO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Allogene (ALLO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Allogene (ALLO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Allogene (ALLO) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Allogene (ALLO) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What were the key takeaways from Allogene's earnings call?What is Allogene's latest dividend and current dividend yield?What guidance did Allogene's management provide for the next earnings period?What does Allogene do and what are its main business segments?What is Allogene's gross profit margin?What is the market's earnings forecast for Allogene next quarter?Did Allogene beat or miss consensus estimates last quarter?What factors drove the changes in Allogene's revenue and profit?
